Mechanism of Action: Topoisomerase 2 Inhibitors
✉ Email this page to a colleague
Drugs with Mechanism of Action: Topoisomerase 2 Inhibitors
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | BLUJEPA | gepotidacin mesylate | TABLET;ORAL | 218230-001 | Mar 25, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Glaxosmithkline | BLUJEPA | gepotidacin mesylate | TABLET;ORAL | 218230-001 | Mar 25, 2025 | RX | Yes | Yes | 10,702,521 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Glaxosmithkline | BLUJEPA | gepotidacin mesylate | TABLET;ORAL | 218230-001 | Mar 25, 2025 | RX | Yes | Yes | 12,528,809 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Glaxosmithkline | BLUJEPA | gepotidacin mesylate | TABLET;ORAL | 218230-001 | Mar 25, 2025 | RX | Yes | Yes | 8,389,524 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Glaxosmithkline | BLUJEPA | gepotidacin mesylate | TABLET;ORAL | 218230-001 | Mar 25, 2025 | RX | Yes | Yes | 11,229,646 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
